Organogenesis Holdings Inc.
Close on Oct 19, 2026
- Market cap
- $131.25M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $42.80M | $-0.77 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $36.30M | $-0.44 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | During market hours | $225.61M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $150.50M | $0.11 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $100.80M | $-0.10 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $86.70M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | During market hours | $126.70M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $115.20M | $0.09 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Total net revenue | year ending December 31, 2026 | $179.00M to $215.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Organogenesis filed with the SEC
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
Organogenesis Provides Update on Second Phase 3
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Organogenesis 22OA (Second Phase 3 ReNu Study)
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
Material agreement · Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
FORWARD LOOKING STATEMENTS & OTHER IMPORTANT CAUTIONS This
Regulation FD disclosure · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Expands Manufacturing Capacity to Support Future Growth
Material agreement · Other events · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Announces $130 million Private Placement Offering of Series A Convertible Preferred Stock
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
Other events · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance
Results of operations · EX-99 to Form 8-K
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Introduces Fiscal Year 2022 Guidance
Results of operations · EX-99.1 to Form 8-K
Organogenesis Holdings Inc. Reports Third Quarter and First Nine Months 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K